Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
•Journal Article
Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease.
Bertrand Vos,Christophe Moreno,Nathalie Nagy,Françoise Fery,Miriam Cnop,Pierre Vereerstraeten,Jacques Devière,Michael Adler +7 more
TL;DR: Lean-NAFLD is a new unrecognized clinicopathological entity, a frequent cause of cryptogenic liver disease, which is evaluated based on a large series of liver biopsies.
Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids
Christophe Moreno,Pierre Deltenre,Pierre Deltenre,Christelle Senterre,Alexandre Louvet,Thierry Gustot,B. Bastens,Axel-Benoit Hittelet,Marie-Astrid Ma Piquet,Wim Laleman,Hans Orlent,L Lasser,Thomas Sersté,Peter Stärkel,Xavier X De Koninck,Sergio Negrin Dastis,Jean Delwaide,Isabelle Colle,Chantal de Galocsy,Sven Francque,Philippe Langlet,V Putzeys,Hendrik Reynaert,Delphine Degré,Eric Trepo +24 more
TL;DR: In a randomized trial of patients with severe AH treated with corticosteroids, it was found that intensive enteral nutrition was difficult to implement and did not increase survival, so adequate nutritional intake should be a main goal for treatment.
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
Massimo Puoti,Graham R. Foster,Stanley Wang,David Mutimer,E.J. Gane,Christophe Moreno,Ting-Tsung Chang,Samuel S.S. Lee,Rui Tato Marinho,Jean-François Dufour,Stanislas Pol,Christophe Hézode,Stuart C. Gordon,Simone I. Strasser,Paul J. Thuluvath,Zhenzhen Zhang,Sandra S. Lovell,Tami Pilot-Matias,Federico J. Mensa +18 more
TL;DR: G/P therapy for eight weeks in patients with chronic HCV GT 1-6 infection without cirrhosis achieved an overall SVR12 rate of 98% irrespective of baseline patient or viral characteristics, demonstrating that the optimal treatment duration in this population is eight weeks.
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs
Amber Arain,Suzanne Bourgeois,C de Galocsy,Jean Henrion,Pierre Deltenre,F D'Heygere,Christophe George,B. Bastens,L Van Overbeke,Rita Verrando,Liesbeth Bruckers,Catharina Matheï,Frank Buntinx,H. Van Vlierberghe,Sven Francque,Wim Laleman,Christophe Moreno,F Janssens,Frederik Nevens,Geert Robaeys,Geert Robaeys +20 more
TL;DR: There are no reasons to exclude PWID from treatment with boceprevir, telaprevir and novel antiviral therapies, and in a cohort of HCV patients infected with genotype 1 in Belgium, treatment outcome of patients infected due to IV drug use was analyzed and compared with patients who have no history of substance use.
Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas.
Christine Francois,Roland Van Velthoven,Olivier De Lathouwer,Christophe Moreno,Alexandre Peltier,Herbert Kaltner,Isabelle Salmon,Hans-Joachim Gabius,André Danguy,Christine Decaestecker,Robert Kiss +10 more
TL;DR: Modifications to the expression of galectins and galectin-3, but not of T antigen, parallel an increase in RCC aggressiveness, which can be associated with unfavorable prognoses for patients with grade II or III RCCs.